BridgeBio Pharma, Inc. (FRA:2CL)

BridgeBio Pharma Statistics

Total Valuation

FRA:2CL has a market cap or net worth of EUR 11.90 billion. The enterprise value is 12.95 billion.

Market Cap	11.90B
Enterprise Value	12.95B

Important Dates

The next estimated earnings date is Friday, February 20, 2026.

Earnings Date	Feb 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	192.71M
Shares Outstanding	n/a
Shares Change (YoY)	+4.48%
Shares Change (QoQ)	+0.70%
Owned by Insiders (%)	4.29%
Owned by Institutions (%)	82.97%
Float	155.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	39.46
PB Ratio	-7.26
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-19.06
EV / Sales	42.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-25.94

Financial Position

The company has a current ratio of 3.88

Current Ratio	3.88
Quick Ratio	3.52
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-3.17
Interest Coverage	-3.67

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-43.47%
Return on Invested Capital (ROIC)	-161.27%
Return on Capital Employed (ROCE)	-74.01%
Revenue Per Employee	414,185
Profits Per Employee	-933,219
Employee Count	730
Asset Turnover	0.43
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:2CL has paid 1.46 million in taxes.

Income Tax	1.46M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +149.25% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+149.25%
50-Day Moving Average	50.98
200-Day Moving Average	39.26
Relative Strength Index (RSI)	70.46
Average Volume (20 Days)	17

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.71

Income Statement

In the last 12 months, FRA:2CL had revenue of EUR 301.53 million and -679.38 million in losses. Loss per share was -3.57.

Revenue	301.53M
Gross Profit	288.79M
Operating Income	-493.03M
Pretax Income	-685.24M
Net Income	-679.38M
EBITDA	-488.45M
EBIT	-493.03M
Loss Per Share	-3.57

Balance Sheet

The company has 550.54 million in cash and 1.59 billion in debt, giving a net cash position of -1.03 billion.

Cash & Cash Equivalents	550.54M
Total Debt	1.59B
Net Cash	-1.03B
Net Cash Per Share	n/a
Equity (Book Value)	-1.64B
Book Value Per Share	-8.55
Working Capital	530.80M

Cash Flow

In the last 12 months, operating cash flow was -498.44 million and capital expenditures -946,905, giving a free cash flow of -499.39 million.

Operating Cash Flow	-498.44M
Capital Expenditures	-946,905
Free Cash Flow	-499.39M
FCF Per Share	n/a

Margins

Gross margin is 95.78%, with operating and profit margins of -163.51% and -225.31%.

Gross Margin	95.78%
Operating Margin	-163.51%
Pretax Margin	-227.26%
Profit Margin	-225.31%
EBITDA Margin	-161.99%
EBIT Margin	-163.51%
FCF Margin	n/a

Dividends & Yields

FRA:2CL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.48%
Shareholder Yield	-4.48%
Earnings Yield	-5.71%
FCF Yield	-4.20%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:2CL has an Altman Z-Score of -4.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.49
Piotroski F-Score	3